Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 03:46 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Use of Low Sensitivity Pregnancy Test for Self-assessment of Medical Abortion

ClinicalTrials.gov · NCT02231619 · Registry updated: 2015-11-09

Condition / research focus: Completion of Medical Abortion
Sponsor: University of Cape Town
Countries with listed sites: South Africa
Registry dates and results: Start: 2014-08. Completion: 2015-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Baseline verbal instruction on LSUPT (behavioral) — also listed as: Low sensitivity urine pregnancy test

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Nolungile Youth Clinic, Khayelitsha
Cape Town, Western Province, South Africa
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique

ClinicalTrials.gov · NCT01497197 · Registry updated: 2015-11-09

Condition / research focus: Infertility; Fertility; Follicle Stimulating Hormone Deficiency
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2012-05. Completion: 2014-01 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GONAL-f® (drug)
Luveris® (drug)
Recombinant human chorionic gonadotropin (r-hCG) (biological)

Where the study takes place — 1 listed sites

Merck Serono Research Site
Dubai, United Arab Emirates
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

IVF/ICSI Protocols in Poor Responders With Growth Hormone

ClinicalTrials.gov · NCT01897324 · Registry updated: 2015-10-20

Condition / research focus: Female Infertility Due to Diminished Ovarian Reserve
Sponsor: Woman's Health University Hospital, Egypt
Countries with listed sites: Egypt
Registry dates and results: Start: 2013-07. Completion: 2015-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone (Norditropin, Novo nordisk) (drug)

Where the study takes place — 1 listed sites

private IVF medical center
Giza, Cairo Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )

ClinicalTrials.gov · NCT02551367 · Registry updated: 2015-09-16

Condition / research focus: Anovulation; Polycystic Ovary Syndrome
Sponsor: mostafa gomaa hamid halawa
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-10. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole (drug) — also listed as: femara
Clomiphene citrate (drug) — also listed as: clomid
hcg hormone (drug) — also listed as: pregnyl

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion

ClinicalTrials.gov · NCT02179944 · Registry updated: 2015-08-17

Condition / research focus: Undesired Pregnancy
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2014-07. Completion: 2015-03 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Planned Parenthood
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Metformin for the Treatment of Unexplained Oligozspermia

ClinicalTrials.gov · NCT01529177 · Registry updated: 2015-08-07

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2012-02. Completion: 2017-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin / clomid / hCG (drug) — also listed as: Glucophage / clomiphene citrate / choriomon
Clomiphene citrate / hCG (drug) — also listed as: Clomid / choriomon

Where the study takes place — 1 listed sites

The Egyptian IVF-ET center
Cairo, Cairo Governorate, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin

ClinicalTrials.gov · NCT01638988 · Registry updated: 2015-07-28

Condition / research focus: Polycystic Ovary Syndrome; Insulin Resistance
Sponsor: Clinique Ovo
Countries with listed sites: Canada
Registry dates and results: Start: 2013-09. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug)
Clomiphene citrate (drug)

Where the study takes place — 1 listed sites

Clinique Ovo
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Use of Corifolitropin Alfa in Oocyte Donors

ClinicalTrials.gov · NCT02213627 · Registry updated: 2015-07-17

Condition / research focus: Female Reproductive Problem; Infertility
Sponsor: IVI Madrid
Countries with listed sites: Spain
Registry dates and results: Start: 2014-10. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Elonva 100 micrograms
Recombinant FSH (drug) — also listed as: Puregon 50 IU
HP-hMG (drug) — also listed as: Menopur 600 IU

Where the study takes place — 1 listed sites

IVI Madrid
Madrid, Madrid, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.

ClinicalTrials.gov · NCT02004626 · Registry updated: 2015-07-16

Condition / research focus: Pressure Ulcer
Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda.
Countries with listed sites: Brazil
Registry dates and results: Start: 2015-01. Completion: 2015-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Collagenase (drug)
Kollagenase (drug)

Where the study takes place — 1 listed sites

Clínica Dr. Norton Sayeg Ltda
São Paulo, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)

ClinicalTrials.gov · NCT01204840 · Registry updated: 2015-07-01

Condition / research focus: Infertility; Poor Ovarian Reserve
Sponsor: Ottawa Fertility Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2010-09. Completion: 2015-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth Hormone (drug) — also listed as: Saizen (Somatoptropin; Human growth hormone)
Patch protocol (drug)

Where the study takes place — 1 listed sites

Ottawa Fertililty Centre
Ottawa, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Corifollitropin Alfa Versus Follitropin Beta in High Responders

ClinicalTrials.gov · NCT02471677 · Registry updated: 2015-06-22

Condition / research focus: Infertility
Sponsor: Eugonia
Countries with listed sites: Greece
Registry dates and results: Start: 2015-09. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Elonva (drug) — also listed as: corifollitropin alfa
Puregon (drug) — also listed as: follitropin beta

Where the study takes place — 1 listed sites

Eugonia Unit of Assisted Reproduction
Athens, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures

ClinicalTrials.gov · NCT02048891 · Registry updated: 2015-06-08

Condition / research focus: Infertility
Sponsor: Rambam Health Care Campus
Countries with listed sites: Israel
Registry dates and results: Start: 2014-10. Completion: 2015-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist trigger (drug) — also listed as: Oovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
hCG trigger (drug) — also listed as: Ovulation trigger with Ovitrelle 250 microgram., Luteal support with daily progesterone gel = Crinone 8%

Where the study takes place — 1 listed sites

IVF Unit, Rambam medical Center
Haifa, Israel, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

IUI Schedule in Cases of High Progesterone

ClinicalTrials.gov · NCT02447588 · Registry updated: 2015-05-19

Condition / research focus: Infertility
Sponsor: IVI Madrid
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-07. Completion: 2016-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IAD at 36 hours (other)
IAD at 24 hours (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Biomarkers of Ovarian Reserve and Correlation With IVF Treatments

ClinicalTrials.gov · NCT02442895 · Registry updated: 2015-05-13

Condition / research focus: Pregnancy, Ovarian
Sponsor: U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti
Countries with listed sites: Italy
Registry dates and results: Start: 2014-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Azienda Ospedaliero Universitaria Consorziale Policlinico
Bari, Bari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Gonadotropin Type in Ovarian Stimulation

ClinicalTrials.gov · NCT02437032 · Registry updated: 2015-05-07

Condition / research focus: Infertility
Sponsor: IVI Madrid
Countries with listed sites: No country reported
Registry dates and results: Start: 2009-04. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant FSH (drug) — also listed as: Gonal-F
Urinary FSH (drug) — also listed as: Fostipur
hMG (drug) — also listed as: hMG-Lepori

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles

ClinicalTrials.gov · NCT02251925 · Registry updated: 2015-05-06

Condition / research focus: Infertility
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2012-09. Completion: 2015-11 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

frozen Embryo transfer (biological)
10,000U hCG injection (drug)
GnRH agonist (Superfact) (drug)
administration of 6 mg Estradiol valerate (drug)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT02140515 · Registry updated: 2015-05-06

Condition / research focus: Infertility
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2012-11. Completion: 2016-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lutropin alfa (drug) — also listed as: Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
Follitropin alfa and Lutropin alfa (drug) — also listed as: Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH) and, Lutropin alfa: Luveris or Recombinant Luteinizing Hormone (rLH)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3SuspendedINTERVENTIONAL

Efficacy of Ovarian Stimulation Based on FSHR Genotype Status

ClinicalTrials.gov · NCT00749853 · Registry updated: 2015-05-05

Condition / research focus: Sterility
Sponsor: Medical University of Vienna
Countries with listed sites: Austria
Registry dates and results: Start: 2015-05. Completion: 2015-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

follicle stimulating hormone (drug) — also listed as: buserelin, r-hFSH, r-hLH
follicle stimulating hormone (drug) — also listed as: buserelin, r-hFSH, HCG

Where the study takes place — 1 listed sites

University of Vienna
Vienna, State of Vienna, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

ClinicalTrials.gov · NCT02427529 · Registry updated: 2015-04-28

Condition / research focus: HCG
Sponsor: Dr. Emma's Corporation
Countries with listed sites: United States
Registry dates and results: Start: 2011-05. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotropin (drug) — also listed as: Pregnyl, Novarel
Placebo (drug)
Low calorie diet (other)

Where the study takes place — 1 listed sites

Dr. Emma's Corporation
Colts Neck, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients

ClinicalTrials.gov · NCT00870025 · Registry updated: 2015-04-22

Condition / research focus: Ovarian Response
Sponsor: IVI Madrid
Countries with listed sites: Spain
Registry dates and results: Start: 2008-10. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (biological)
placebo (biological)

Where the study takes place — 1 listed sites

IVI-Madrid
Madrid, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 03:46 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Use of Low Sensitivity Pregnancy Test for Self-assessment of Medical Abortion

ClinicalTrials.gov · NCT02231619 · Registry updated: 2015-11-09

Condition / research focus: Completion of Medical Abortion
Sponsor: University of Cape Town
Countries with listed sites: South Africa
Registry dates and results: Start: 2014-08. Completion: 2015-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Baseline verbal instruction on LSUPT (behavioral) — also listed as: Low sensitivity urine pregnancy test

Where the study takes place — 1 listed sites

Nolungile Youth Clinic, Khayelitsha
Cape Town, Western Province, South Africa
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique

ClinicalTrials.gov · NCT01497197 · Registry updated: 2015-11-09

Condition / research focus: Infertility; Fertility; Follicle Stimulating Hormone Deficiency
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2012-05. Completion: 2014-01 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GONAL-f® (drug)
Luveris® (drug)
Recombinant human chorionic gonadotropin (r-hCG) (biological)

Where the study takes place — 1 listed sites

Merck Serono Research Site
Dubai, United Arab Emirates
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

IVF/ICSI Protocols in Poor Responders With Growth Hormone

ClinicalTrials.gov · NCT01897324 · Registry updated: 2015-10-20

Condition / research focus: Female Infertility Due to Diminished Ovarian Reserve
Sponsor: Woman's Health University Hospital, Egypt
Countries with listed sites: Egypt
Registry dates and results: Start: 2013-07. Completion: 2015-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone (Norditropin, Novo nordisk) (drug)

Where the study takes place — 1 listed sites

private IVF medical center
Giza, Cairo Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )

ClinicalTrials.gov · NCT02551367 · Registry updated: 2015-09-16

Condition / research focus: Anovulation; Polycystic Ovary Syndrome
Sponsor: mostafa gomaa hamid halawa
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-10. Completion: 2016-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole (drug) — also listed as: femara
Clomiphene citrate (drug) — also listed as: clomid
hcg hormone (drug) — also listed as: pregnyl

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion

ClinicalTrials.gov · NCT02179944 · Registry updated: 2015-08-17

Condition / research focus: Undesired Pregnancy
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2014-07. Completion: 2015-03 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Planned Parenthood
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Metformin for the Treatment of Unexplained Oligozspermia

ClinicalTrials.gov · NCT01529177 · Registry updated: 2015-08-07

Condition / research focus: Infertility
Sponsor: The Egyptian IVF-ET Center
Countries with listed sites: Egypt
Registry dates and results: Start: 2012-02. Completion: 2017-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin / clomid / hCG (drug) — also listed as: Glucophage / clomiphene citrate / choriomon
Clomiphene citrate / hCG (drug) — also listed as: Clomid / choriomon

Where the study takes place — 1 listed sites

The Egyptian IVF-ET center
Cairo, Cairo Governorate, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin

ClinicalTrials.gov · NCT01638988 · Registry updated: 2015-07-28

Condition / research focus: Polycystic Ovary Syndrome; Insulin Resistance
Sponsor: Clinique Ovo
Countries with listed sites: Canada
Registry dates and results: Start: 2013-09. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug)
Clomiphene citrate (drug)

Where the study takes place — 1 listed sites

Clinique Ovo
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Use of Corifolitropin Alfa in Oocyte Donors

ClinicalTrials.gov · NCT02213627 · Registry updated: 2015-07-17

Condition / research focus: Female Reproductive Problem; Infertility
Sponsor: IVI Madrid
Countries with listed sites: Spain
Registry dates and results: Start: 2014-10. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Elonva 100 micrograms
Recombinant FSH (drug) — also listed as: Puregon 50 IU
HP-hMG (drug) — also listed as: Menopur 600 IU

Where the study takes place — 1 listed sites

IVI Madrid
Madrid, Madrid, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.

ClinicalTrials.gov · NCT02004626 · Registry updated: 2015-07-16

Condition / research focus: Pressure Ulcer
Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda.
Countries with listed sites: Brazil
Registry dates and results: Start: 2015-01. Completion: 2015-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Collagenase (drug)
Kollagenase (drug)

Where the study takes place — 1 listed sites

Clínica Dr. Norton Sayeg Ltda
São Paulo, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)

ClinicalTrials.gov · NCT01204840 · Registry updated: 2015-07-01

Condition / research focus: Infertility; Poor Ovarian Reserve
Sponsor: Ottawa Fertility Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2010-09. Completion: 2015-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth Hormone (drug) — also listed as: Saizen (Somatoptropin; Human growth hormone)
Patch protocol (drug)

Where the study takes place — 1 listed sites

Ottawa Fertililty Centre
Ottawa, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Corifollitropin Alfa Versus Follitropin Beta in High Responders

ClinicalTrials.gov · NCT02471677 · Registry updated: 2015-06-22

Condition / research focus: Infertility
Sponsor: Eugonia
Countries with listed sites: Greece
Registry dates and results: Start: 2015-09. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Elonva (drug) — also listed as: corifollitropin alfa
Puregon (drug) — also listed as: follitropin beta

Where the study takes place — 1 listed sites

Eugonia Unit of Assisted Reproduction
Athens, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures

ClinicalTrials.gov · NCT02048891 · Registry updated: 2015-06-08

Condition / research focus: Infertility
Sponsor: Rambam Health Care Campus
Countries with listed sites: Israel
Registry dates and results: Start: 2014-10. Completion: 2015-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist trigger (drug) — also listed as: Oovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
hCG trigger (drug) — also listed as: Ovulation trigger with Ovitrelle 250 microgram., Luteal support with daily progesterone gel = Crinone 8%

Where the study takes place — 1 listed sites

IVF Unit, Rambam medical Center
Haifa, Israel, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

IUI Schedule in Cases of High Progesterone

ClinicalTrials.gov · NCT02447588 · Registry updated: 2015-05-19

Condition / research focus: Infertility
Sponsor: IVI Madrid
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-07. Completion: 2016-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IAD at 36 hours (other)
IAD at 24 hours (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Biomarkers of Ovarian Reserve and Correlation With IVF Treatments

ClinicalTrials.gov · NCT02442895 · Registry updated: 2015-05-13

Condition / research focus: Pregnancy, Ovarian
Sponsor: U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti
Countries with listed sites: Italy
Registry dates and results: Start: 2014-02. Completion: 2015-02 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Azienda Ospedaliero Universitaria Consorziale Policlinico
Bari, Bari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Gonadotropin Type in Ovarian Stimulation

ClinicalTrials.gov · NCT02437032 · Registry updated: 2015-05-07

Condition / research focus: Infertility
Sponsor: IVI Madrid
Countries with listed sites: No country reported
Registry dates and results: Start: 2009-04. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant FSH (drug) — also listed as: Gonal-F
Urinary FSH (drug) — also listed as: Fostipur
hMG (drug) — also listed as: hMG-Lepori

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles

ClinicalTrials.gov · NCT02251925 · Registry updated: 2015-05-06

Condition / research focus: Infertility
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2012-09. Completion: 2015-11 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

frozen Embryo transfer (biological)
10,000U hCG injection (drug)
GnRH agonist (Superfact) (drug)
administration of 6 mg Estradiol valerate (drug)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT02140515 · Registry updated: 2015-05-06

Condition / research focus: Infertility
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2012-11. Completion: 2016-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lutropin alfa (drug) — also listed as: Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
Follitropin alfa and Lutropin alfa (drug) — also listed as: Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH) and, Lutropin alfa: Luveris or Recombinant Luteinizing Hormone (rLH)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3SuspendedINTERVENTIONAL

Efficacy of Ovarian Stimulation Based on FSHR Genotype Status

ClinicalTrials.gov · NCT00749853 · Registry updated: 2015-05-05

Condition / research focus: Sterility
Sponsor: Medical University of Vienna
Countries with listed sites: Austria
Registry dates and results: Start: 2015-05. Completion: 2015-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

follicle stimulating hormone (drug) — also listed as: buserelin, r-hFSH, r-hLH
follicle stimulating hormone (drug) — also listed as: buserelin, r-hFSH, HCG

Where the study takes place — 1 listed sites

University of Vienna
Vienna, State of Vienna, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

ClinicalTrials.gov · NCT02427529 · Registry updated: 2015-04-28

Condition / research focus: HCG
Sponsor: Dr. Emma's Corporation
Countries with listed sites: United States
Registry dates and results: Start: 2011-05. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotropin (drug) — also listed as: Pregnyl, Novarel
Placebo (drug)
Low calorie diet (other)

Where the study takes place — 1 listed sites

Dr. Emma's Corporation
Colts Neck, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients

ClinicalTrials.gov · NCT00870025 · Registry updated: 2015-04-22

Condition / research focus: Ovarian Response
Sponsor: IVI Madrid
Countries with listed sites: Spain
Registry dates and results: Start: 2008-10. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (biological)
placebo (biological)

Where the study takes place — 1 listed sites

IVI-Madrid
Madrid, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →